Loading...
•
Dec 31, 2021
Replimune Q3 2022 Earnings Report
Replimune announced financial results for the third fiscal quarter ended December 31, 2021 and provided a business update.
Key Takeaways
Replimune Group Inc. reported financial results for the fiscal third quarter ended December 31, 2021, and provided a business update, highlighting upcoming milestones and data presentations.
Investor event planned to present commercial strategy and RP2/3 development plans.
Plans to establish a broad, high-value skin cancer franchise with RP1.
Overview of mid-stage development plans for RP2/3.
Release of data from registrational studies expected to highlight the platform’s potential.
Replimune
Replimune
Forward Guidance
Replimune believes that existing cash, cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.